{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:56:07Z","timestamp":1768902967863,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T00:00:00Z","timestamp":1691366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010154","name":"Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n de la Investigaci\u00f3n en Salud de Sevilla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["CP19\/00159"],"award-info":[{"award-number":["CP19\/00159"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["FI19\/00304"],"award-info":[{"award-number":["FI19\/00304"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["FI21\/00165"],"award-info":[{"award-number":["FI21\/00165"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This was a substudy of a Phase IV, randomized clinical trial (ClinicalTrials.gov identifier: NCT04295460) aiming to compare the activity of dolutegravir\/lamivudine versus dolutegravir plus tenofovir alafenamide\/emtricitabine (DTG\u200a+\u200aTAF\/FTC) in the male genital tract.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were asymptomatic adults without sexually transmitted diseases, treatment-naive people living with HIV (PLWH), with CD4+ T cell counts &amp;gt;200 cells\/mm3 and plasma HIV-1-RNA levels &amp;gt;5000 and &amp;lt;500\u200a000 copies\/mL, randomized (1:1) to DTG\u200a+\u200aTAF\/FTC or dolutegravir\/lamivudine. Blood plasma (BP) and seminal plasma (SP) were collected at baseline and Weeks 4, 8, 12 and 24. HIV-1-RNA was measured in BP and SP using the Cobas 6800 system (Roche Diagnostics) with a lower detection limit of 20 copies\/mL. The primary efficacy endpoint was the proportion of subjects with undetectable SP HIV-1-RNA at Week 12 by intention-to-treat analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifteen participants in the DTG\u200a+\u200aTAF\/FTC and 16 in the dolutegravir\/lamivudine arms were analysed, with basal SP viral load of 4.81 (4.30\u20135.43) and 4.76 (4.09\u20135.23), P\u200a=\u200a0.469, respectively. At Week 12, only one participant in each treatment arm had a detectable SP HIV-1-RNA (DTG\u200a+\u200aTAF\/FTC, 141 copies\/mL; dolutegravir\/lamivudine, 61 copies\/mL). Based on the estimated means, there was no significant difference in the decay of HIV-1-RNA in both BP and SP over time between the two arms of treatment (F\u200a=\u200a0.452, P\u200a=\u200a0.662, and F\u200a=\u200a1.147, P\u200a=\u200a0.185, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>After 12 weeks of treatment, there were no differences in the percentage of undetectable SP HIV-1-RNA in naive PLWH who started dolutegravir\/lamivudine compared with DTG\u200a+\u200aTAF\/FTC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkad245","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T07:36:59Z","timestamp":1691393819000},"page":"2354-2360","source":"Crossref","is-referenced-by-count":3,"title":["Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir\/lamivudine versus dolutegravir plus emtricitabine\/tenofovir alafenamide in treatment-naive people living with HIV"],"prefix":"10.1093","volume":"78","author":[{"given":"Abraham","family":"Saborido-Alconchel","sequence":"first","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Serna-Gallego","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-527X","authenticated-orcid":false,"given":"Luis E","family":"Lopez-Cortes","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit (Department of Medicine, School of Medicine). Instituto de Biomedicina de Sevilla\/University Hospital Virgen. Seville. Spain. Macarena\/CSIC\/Universidad de Sevilla . CIBERINFEC, Instituto de Salud Carlos III, Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Trujillo-Rodriguez","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Praena-Fernandez","sequence":"additional","affiliation":[{"name":"Departamento de Estad\u00edstica e Investigaci\u00f3n Operativa. Facultad de Ciencias . Universidad de Granada. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Dominguez-Macias","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Lozano","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Mu\u00f1oz-Muela","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Roca-Oporto","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar","family":"Sotomayor","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Herrero","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-1574","authenticated-orcid":false,"given":"Alicia","family":"Gutierrez-Valencia","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-3458","authenticated-orcid":false,"given":"Luis F","family":"Lopez-Cortes","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Microbiology Clinical Unit . Instituto de Biomedicina de Sevilla\/University Hospital Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla. Sevilla. \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"2023110802523557000_dkad245-B1","doi-asserted-by":"crossref","first-page":"77ra29","DOI":"10.1126\/scitranslmed.3001888","article-title":"Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission","volume":"3","author":"Baeten","year":"2011","journal-title":"Sci Transl Med"},{"key":"2023110802523557000_dkad245-B2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJM200003303421303","article-title":"Viral load and heterosexual transmission of human immunodeficiency virus type 1","volume":"342","author":"Quinn","year":"2000","journal-title":"N Engl J Med"},{"key":"2023110802523557000_dkad245-B3","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3018(18)30132-2","article-title":"Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study","volume":"5","author":"Bavinton","year":"2018","journal-title":"Lancet HIV"},{"key":"2023110802523557000_dkad245-B4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"2023110802523557000_dkad245-B5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"2023110802523557000_dkad245-B6","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","article-title":"Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study","volume":"393","author":"Rodger","year":"2019","journal-title":"Lancet"},{"key":"2023110802523557000_dkad245-B7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.2016.5148","article-title":"Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy","volume":"316","author":"Rodger","year":"2016","journal-title":"JAMA"},{"key":"2023110802523557000_dkad245-B8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/infdis\/jiw131","article-title":"Seminal HIV-1 RNA detection in heterosexual African men initiating antiretroviral therapy","volume":"214","author":"Mujugira","year":"2016","journal-title":"J Infect Dis"},{"key":"2023110802523557000_dkad245-B9","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"2023110802523557000_dkad245-B10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/cid\/cix358","article-title":"Viral kinetics in semen with different antiretroviral families in treatment-naive human immunodeficiency virus-infected patients: a randomized trial","volume":"65","author":"Gutierrez-Valencia","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023110802523557000_dkad245-B11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/infdis\/jiab336","article-title":"HIV-1 RNA kinetics in blood plasma and in seminal plasma of men starting a dolutegravir-based triple-combination regimen at the time of primary HIV-1 infection","volume":"225","author":"Ghosn","year":"2022","journal-title":"J Infect Dis"},{"key":"2023110802523557000_dkad245-B12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/aid.2018.0090","article-title":"Short communication: discordance of HIV-1 viral load from paired blood and seminal plasma samples in a Chinese men who have sex with men population","volume":"35","author":"Zhang","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023110802523557000_dkad245-B13","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2022"},{"key":"2023110802523557000_dkad245-B14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/QAI.0b013e31816de21e","article-title":"Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men","volume":"48","author":"Dumond","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023110802523557000_dkad245-B15","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1086\/315149","article-title":"Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden","volume":"180","author":"Pereira","year":"1999","journal-title":"J Infect Dis"},{"key":"2023110802523557000_dkad245-B16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1086\/341209","article-title":"The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS Clinical Trials Group Study 850)","volume":"186","author":"Pereira","year":"2002","journal-title":"J Infect Dis"},{"key":"2023110802523557000_dkad245-B17","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1128\/AAC.01517-15","article-title":"Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study","volume":"59","author":"Valade","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110802523557000_dkad245-B18","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1089\/aid.2016.0008","article-title":"Intracellular tenofovir and emtricitabine anabolites in genital, rectal, and blood compartments from first dose to steady state","volume":"32","author":"Seifert","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023110802523557000_dkad245-B19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/FTD.0b013e31811fef29","article-title":"Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen","volume":"29","author":"Lowe","year":"2007","journal-title":"Ther Drug Monit"},{"key":"2023110802523557000_dkad245-B20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/QAI.0b013e3181632cc3","article-title":"The pharmacokinetics and viral activity of tenofovir in the male genital tract","volume":"47","author":"Vourvahis","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023110802523557000_dkad245-B21","doi-asserted-by":"crossref","first-page":"e02062","DOI":"10.1128\/AAC.02062-16","article-title":"Population pharmacokinetic modeling of tenofovir in the genital tract of male HIV-infected patients","volume":"61","author":"Valade","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023110802523557000_dkad245-B22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/ciy1074","article-title":"Seminal tenofovir concentrations, viral suppression, and semen quality with tenofovir alafenamide, compared with tenofovir disoproxil fumarate (Spanish HIV\/AIDS Research Network, PreEC\/RIS 40)","volume":"69","author":"Imaz","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023110802523557000_dkad245-B23","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/infdis\/jiw406","article-title":"HIV-1-RNA decay and dolutegravir concentrations in semen of patients starting a first antiretroviral regimen","volume":"214","author":"Imaz","year":"2016","journal-title":"J Infect Dis"},{"key":"2023110802523557000_dkad245-B24","doi-asserted-by":"crossref","first-page":"e1991","DOI":"10.1093\/cid\/ciaa1416","article-title":"Dynamics of the decay of human immunodeficiency virus (HIV) RNA and distribution of bictegravir in the genital tract and rectum in antiretroviral-naive adults living with HIV-1 treated with bictegravir\/emtricitabine\/tenofovir alafenamide (Spanish HIV\/AIDS Research Network, PreEC\/RIS 58)","volume":"73","author":"Imaz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023110802523557000_dkad245-B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jcv.2018.11.002","article-title":"HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen","volume":"109","author":"Fabrizio","year":"2018","journal-title":"J Clin Virol"},{"key":"2023110802523557000_dkad245-B26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jac\/dkz482","article-title":"Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir\/abacavir\/lamivudine","volume":"75","author":"Fernandez-Gonzalez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023110802523557000_dkad245-B27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/jac\/dkab427","article-title":"HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir-versus darunavir-based combined ART (cART) regimens during primary HIV infection","volume":"77","author":"Mariaggi","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2023110802523557000_dkad245-B28","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/QAI.0000000000001863","article-title":"Genital HIV-1 shedding with dolutegravir (DTG) plus lamivudine (3TC) dual therapy","volume":"79","author":"Gianella","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023110802523557000_dkad245-B29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/QAI.0000000000001019","article-title":"HIV Transmission risk persists during the first 6 months of antiretroviral therapy","volume":"72","author":"Mujugira","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023110802523557000_dkad245-B30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/QAD.0b013e328012b838","article-title":"Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts","volume":"21","author":"Coleman","year":"2007","journal-title":"AIDS"},{"key":"2023110802523557000_dkad245-B31","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jcph.481","article-title":"Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy","volume":"55","author":"Neely","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2023110802523557000_dkad245-B32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/426394","article-title":"Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis","volume":"191","author":"Sha","year":"2005","journal-title":"J Infect Dis"},{"key":"2023110802523557000_dkad245-B33","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1089\/aid.2008.0004","article-title":"Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women","volume":"24","author":"Spear","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023110802523557000_dkad245-B34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/QAI.0000000000000823","article-title":"Systemic immune activation and HIV shedding in the female genital tract","volume":"71","author":"Spencer","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023110802523557000_dkad245-B35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/651696","article-title":"Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial","volume":"201","author":"Tanton","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/9\/2354\/52824000\/dkad245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/9\/2354\/52824000\/dkad245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T02:53:06Z","timestamp":1699411986000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/9\/2354\/7237989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,7]]},"published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkad245","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,8,7]]}}}